低分子イノベーターCDMOの世界市場レポート 2025年

低分子イノベーターCDMO市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.8％で852億8,000万米ドルに成長します。予測期間の成長は、個別化医療と標的療法の増加、グリーンケミストリーと持続可能性への注目の高まり、新薬の市場投入までの時間短縮の要求、バイオ医薬品パイプラインの拡大、先端療法の出現に起因すると考えられます。予測期間における主な動向としては、バーチャル開発モデルやリモート開発モデルの台頭、製薬業界における連携やパートナーシップの増加、新興国市場へのCDMOサービスの拡大、製造におけるシングルユース技術の活用、CDMOの戦略的開発パートナーへの進化などが挙げられます。

低分子イノベーターCDMO市場の成長は、慢性疾患の有病率の増加によって促進されると予想されます。慢性疾患は1年以上続き、継続的な治療を必要とすることが多く、増加傾向にあります。低分子イノベーターCDMO市場は、製薬会社やバイオテクノロジー企業にサービスを提供し、慢性疾患治療薬の製造において重要な役割を果たしています。2023年1月に発表された全米生物工学情報センター（NCBI）の予測によると、2050年までに米国で少なくとも1つの慢性疾患を持つ50歳以上の人口は、2020年の7,152万2,000人から99.5％急増し、1億4,266万人に達すると予想されています。このように、慢性疾患の有病率の増加は、低分子イノベーターCDMO市場の原動力となっています。

研究開発（R&D）支出の増加は、今後の低分子イノベーターCDMO市場の成長を促進すると予想されます。研究開発費とは、企業や組織が技術革新、製品開発、技術進歩に焦点を当てた活動に割り当てる財源を指します。低分子イノベーターCDMO市場は、製薬企業やバイオテクノロジー企業に専門的かつ効率的なサービスを提供し、創薬・開発プロセスを加速させることで、この上昇を支える重要な役割を担っています。例えば、2023年6月、ベルギーに本拠を置く業界団体でありロビー活動団体である欧州製薬団体連合会（European Federation of Pharmaceutical Industries and Associations）は、研究開発費が2021年の425億3,300万ユーロ（467億9,000万米ドル）から2022年には445億ユーロ（489億5,000万米ドル）に増加し、19億6,700万ユーロ（21億6,000万米ドル）の増加となったと報告しました。このように、研究開発費の増加が低分子イノベーターCDMO市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界低分子イノベーターCDMO PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の低分子イノベーターCDMO市場：成長率分析
• 世界の低分子イノベーターCDMO市場の実績：規模と成長, 2019-2024
• 世界の低分子イノベーターCDMO市場の予測：規模と成長, 2024-2029, 2034F
• 世界低分子イノベーターCDMO総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の低分子イノベーターCDMO市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小分子有効医薬品成分（API）
• 低分子医薬品
• 世界の低分子イノベーターCDMO市場：ステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前臨床
• 臨床
• 商業用
• 世界の低分子イノベーターCDMO市場治療による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心血管疾患
• 腫瘍学
• 呼吸器疾患
• 神経学
• 代謝障害
• 感染症
• その他の治療法
• 世界の低分子イノベーターCDMO市場顧客別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬
• バイオテクノロジー
• 世界の低分子イノベーターCDMO市場、小分子有効医薬品成分（API）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 汎用API
• 独自のAPI
• 規制物質
• 世界の低分子イノベーターCDMO市場、低分子医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口固形剤（錠剤、カプセル剤）
• 注射剤
• 局所用製剤
• 液体製剤

第7章 地域別・国別分析

• 世界の低分子イノベーターCDMO市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の低分子イノベーターCDMO市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 低分子イノベーターCDMO市場：競合情勢
• 低分子イノベーターCDMO市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Labcorp Drug Development Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Catalent Inc.
• Wuxi AppTec Co. Ltd.
• Asymchem
• Siegfried holdings
• Recipharm AB
• Almac Sciences Ltd.
• Curia Global Inc.
• Cambrex Corporation
• Piramal Pharma Ltd.
• Hovione
• Corden Pharma GmbH
• Alcami Corporation
• Lifecore Biomedical Inc.
• NovaTech LLC
• Mikart LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 低分子イノベーターCDMO市場2029：新たな機会を提供する国
• 低分子イノベーターCDMO市場2029：新たな機会を提供するセグメント
• 低分子イノベーターCDMO市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

A small molecule innovator Contract Development and Manufacturing Organization (CDMO) refers to a pharmaceutical division that provides contract services for the development and manufacturing of small-molecule drugs. These services are often utilized in clinical trials to gather early relative bioavailability information.

The main product types offered by small molecule innovator CDMOs include small molecule active pharmaceutical ingredient (API) and small molecule drug product. Small molecule API refers to any material or combination of materials intended to be used as an active component in the production of a medication or medical product. The various stages involved in the development and manufacturing process include preclinical, clinical, and commercial stages, and these products are used in therapeutic areas such as cardiovascular disease, oncology, respiratory disorders, neurology, metabolic disorders, infectious disease, and others. The primary customers for small molecule innovator CDMOs are pharmaceutical and biotechnology companies.

The small molecule innovator CDMO market research report is one of a series of new reports from The Business Research Company that provides small molecule innovator CDMO market statistics, including small molecule innovator CDMO industry global market size, regional shares, competitors with a small molecule innovator CDMO market share, detailed small molecule innovator CDMO market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule innovator CDMO industry. This small molecule innovator CDMO market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The small molecule innovator cdmo market size has grown strongly in recent years. It will grow from $56.49 billion in 2024 to $60.88 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to rising demand for outsourcing, increasing complexity of small molecule drugs, increasing focus on time-to-market, cost pressures on pharma companies, and stringent regulatory requirements

The small molecule innovator cdmo market size is expected to see strong growth in the next few years. It will grow to $85.28 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to a rise in personalized medicine and targeted therapies, increased focus on green chemistry and sustainability, demand for faster time-to-market for new drugs, expansion of the biopharmaceutical pipeline, and the emergence of advanced therapies. Major trends in the forecast period include the rise of virtual and remote development models, increased collaboration and partnerships in the pharma industry, expansion of CDMO services to emerging markets, utilization of single-use technologies in manufacturing, and evolution of CDMOs into strategic development partners.

The growth of the small-molecule innovator CDMO market is expected to be fueled by the increasing prevalence of chronic diseases. Chronic diseases, which last a year or longer and often require continuous medical care, are on the rise. The small-molecule innovator CDMO market plays a crucial role in manufacturing medicines for chronic diseases, providing services to pharmaceutical and biotech companies. Projections from the National Center for Biotechnology Information (NCBI) in January 2023 indicate that by 2050, the number of individuals aged 50 and older with at least one chronic illness in the US is anticipated to surge by 99.5%, reaching 142.66 million, up from 71.522 million in 2020. Thus, the increasing prevalence of chronic diseases serves as a driving force for the small-molecule innovator CDMO market.

The increasing expenditures on research and development (R&D) are anticipated to drive the growth of the small-molecule innovator CDMO market in the future. R&D expenditure refers to the financial resources a company or organization allocates for activities focused on innovation, product development, and technological progress. The small-molecule innovator CDMO market is crucial in supporting this rise by offering specialized and efficient services to pharmaceutical and biotechnology companies, which accelerates drug discovery and development processes. For example, in June 2023, the European Federation of Pharmaceutical Industries and Associations, a Belgium-based trade association and lobbying group, reported that R&D expenditures grew from €42,533 million ($46.79 billion) in 2021 to €44,500 million ($48.95 billion) in 2022, representing an increase of €1,967 million ($2.16 billion). Thus, the rise in R&D expenditures is fueling growth in the small-molecule innovator CDMO market.

A prominent trend in the small-molecule CDMO market is the focus on product innovation. Major companies within this market are adopting innovative products to sustain their positions. In May 2023, Oxford Biomedica, a UK-based company, introduced TetraVecta, a next-generation system for CDMO. This technology addresses previous challenges in medicinal development related to payload size, complexity, or interference, thereby facilitating the advancement of in vivo gene treatments.

Strategic partnerships are emerging as a key approach for major companies in the small-molecule innovator CDMO market to provide contract development and manufacturing organization (CDMO) services. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. An example of this approach is the partnership between SST Corporation, a US-based pharmaceutical company, and Viwit Pharmaceuticals, a China-based research-based pharmaceutical and chemical company. Through this collaboration, they aim to enhance market growth in North America by expanding offerings, leveraging expertise, increasing capacity, and providing essential regulatory support to strengthen their competitive edge.

In February 2022, Recipharma AB, a Sweden-based pharmaceutical CDMO, acquired Vibalogics for an undisclosed amount. This acquisition allows Recipharm to utilize Vibalogics' expertise in oncolytic viruses, viral vaccines, and viral vector gene treatments, enabling diversification across multiple technologies and modalities. Vibalogics GmbH is a Germany-based pharmaceutical CDMO.

Major companies operating in the small molecule innovator cdmo market include Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Evonik Industries AG, Lonza Group Ltd. , Labcorp Drug Development, Catalent Inc., Wuxi AppTec Co. Ltd., Asymchem, Siegfried holdings, Recipharm AB, Almac Sciences Ltd., Curia Global Inc., Cambrex Corporation, Piramal Pharma Ltd., Hovione, Corden Pharma GmbH, Alcami Corporation, Lifecore Biomedical Inc., NovaTech LLC, Mikart LLC, Kymanox Corporation, August Bioservices LLC, Lyophilization Technology Inc., LGM Pharma LLC, INCOG BioPharma Services

Asia-Pacific was the largest region in the small molecule innovator CDMO market in 2024. The regions covered in the small molecule innovator cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the small molecule innovator cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The small molecule innovator CDMO market includes revenues earned by entities by manufacturing the drug substance and providing innovation and services such as packaging, serialization, and shipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Small Molecule Innovator CDMO Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on small molecule innovator cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for small molecule innovator cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The small molecule innovator cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Small Molecule Active Pharmaceutical Ingredient(API); Small Molecule Drug Product
• 2) By Stage: Preclinical; Clinical; Commercial
• 3) By Therapeutic: Cardiovascular Disease; Oncology; Respiratory Disorders; Neurology; Metabolic Disorders; Infectious Disease; Other Therapeutics
• 4) By Customer: Pharmaceutical; Biotechnology
• Subsegments:
• 1) By Small Molecule Active Pharmaceutical Ingredient (API): Generic APIs; Proprietary APIs; Controlled Substances
• 2) By Small Molecule Drug Product: Oral Solid Dosage Forms (Tablets, Capsules); Injectable Drug Products; Topical Formulations; Liquid Formulations
• Companies Mentioned: Thermo Fisher Scientific Inc.; Boehringer Ingelheim International GmbH; Evonik Industries AG; Lonza Group Ltd. ; Labcorp Drug Development
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Small Molecule Innovator CDMO Market Characteristics

3. Small Molecule Innovator CDMO Market Trends And Strategies

4. Small Molecule Innovator CDMO Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Small Molecule Innovator CDMO Growth Analysis And Strategic Analysis Framework

• 5.1. Global Small Molecule Innovator CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Small Molecule Innovator CDMO Market Growth Rate Analysis
• 5.4. Global Small Molecule Innovator CDMO Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Small Molecule Innovator CDMO Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Small Molecule Innovator CDMO Total Addressable Market (TAM)

6. Small Molecule Innovator CDMO Market Segmentation

• 6.1. Global Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Molecule Active Pharmaceutical Ingredient(API)
• Small Molecule Drug Product
• 6.2. Global Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preclinical
• Clinical
• Commercial
• 6.3. Global Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular Disease
• Oncology
• Respiratory Disorders
• Neurology
• Metabolic Disorders
• Infectious Disease
• Other Therapeutics
• 6.4. Global Small Molecule Innovator CDMO Market, Segmentation By Customer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical
• Biotechnology
• 6.5. Global Small Molecule Innovator CDMO Market, Sub-Segmentation Of Small Molecule Active Pharmaceutical Ingredient (API), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Generic APIs
• Proprietary APIs
• Controlled Substances
• 6.6. Global Small Molecule Innovator CDMO Market, Sub-Segmentation Of Small Molecule Drug Product, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solid Dosage Forms (Tablets, Capsules)
• Injectable Drug Products
• Topical Formulations
• Liquid Formulations

7. Small Molecule Innovator CDMO Market Regional And Country Analysis

• 7.1. Global Small Molecule Innovator CDMO Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Small Molecule Innovator CDMO Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Small Molecule Innovator CDMO Market

• 8.1. Asia-Pacific Small Molecule Innovator CDMO Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Small Molecule Innovator CDMO Market

• 9.1. China Small Molecule Innovator CDMO Market Overview
• 9.2. China Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Small Molecule Innovator CDMO Market

• 10.1. India Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Small Molecule Innovator CDMO Market

• 11.1. Japan Small Molecule Innovator CDMO Market Overview
• 11.2. Japan Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Small Molecule Innovator CDMO Market

• 12.1. Australia Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Small Molecule Innovator CDMO Market

• 13.1. Indonesia Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Small Molecule Innovator CDMO Market

• 14.1. South Korea Small Molecule Innovator CDMO Market Overview
• 14.2. South Korea Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Small Molecule Innovator CDMO Market

• 15.1. Western Europe Small Molecule Innovator CDMO Market Overview
• 15.2. Western Europe Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Small Molecule Innovator CDMO Market

• 16.1. UK Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Small Molecule Innovator CDMO Market

• 17.1. Germany Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Small Molecule Innovator CDMO Market

• 18.1. France Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Small Molecule Innovator CDMO Market

• 19.1. Italy Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Small Molecule Innovator CDMO Market

• 20.1. Spain Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Small Molecule Innovator CDMO Market

• 21.1. Eastern Europe Small Molecule Innovator CDMO Market Overview
• 21.2. Eastern Europe Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Small Molecule Innovator CDMO Market

• 22.1. Russia Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Small Molecule Innovator CDMO Market

• 23.1. North America Small Molecule Innovator CDMO Market Overview
• 23.2. North America Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Small Molecule Innovator CDMO Market

• 24.1. USA Small Molecule Innovator CDMO Market Overview
• 24.2. USA Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Small Molecule Innovator CDMO Market

• 25.1. Canada Small Molecule Innovator CDMO Market Overview
• 25.2. Canada Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Small Molecule Innovator CDMO Market

• 26.1. South America Small Molecule Innovator CDMO Market Overview
• 26.2. South America Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Small Molecule Innovator CDMO Market

• 27.1. Brazil Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Small Molecule Innovator CDMO Market

• 28.1. Middle East Small Molecule Innovator CDMO Market Overview
• 28.2. Middle East Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Small Molecule Innovator CDMO Market

• 29.1. Africa Small Molecule Innovator CDMO Market Overview
• 29.2. Africa Small Molecule Innovator CDMO Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Small Molecule Innovator CDMO Market, Segmentation By Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Small Molecule Innovator CDMO Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Small Molecule Innovator CDMO Market Competitive Landscape And Company Profiles

• 30.1. Small Molecule Innovator CDMO Market Competitive Landscape
• 30.2. Small Molecule Innovator CDMO Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Evonik Industries AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Lonza Group Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Labcorp Drug Development Overview, Products and Services, Strategy and Financial Analysis

31. Small Molecule Innovator CDMO Market Other Major And Innovative Companies

• 31.1. Catalent Inc.
• 31.2. Wuxi AppTec Co. Ltd.
• 31.3. Asymchem
• 31.4. Siegfried holdings
• 31.5. Recipharm AB
• 31.6. Almac Sciences Ltd.
• 31.7. Curia Global Inc.
• 31.8. Cambrex Corporation
• 31.9. Piramal Pharma Ltd.
• 31.10. Hovione
• 31.11. Corden Pharma GmbH
• 31.12. Alcami Corporation
• 31.13. Lifecore Biomedical Inc.
• 31.14. NovaTech LLC
• 31.15. Mikart LLC

32. Global Small Molecule Innovator CDMO Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Small Molecule Innovator CDMO Market

34. Recent Developments In The Small Molecule Innovator CDMO Market

35. Small Molecule Innovator CDMO Market High Potential Countries, Segments and Strategies

• 35.1 Small Molecule Innovator CDMO Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Small Molecule Innovator CDMO Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Small Molecule Innovator CDMO Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer